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Abstract
The potential role of the cell-of-origin in determining the tumor phenotype has been raised, but not adequately examined.
We hypothesized that distinct cells-of-origin may play a role in determining ovarian tumor phenotype and outcome. Here
we describe a new cell culture medium for in vitro culture of paired normal human ovarian (OV) and fallopian tube (FT)
epithelial cells from donors without cancer. While these cells have been cultured individually for short periods of time, to
our knowledge this is the first long-term culture of both cell types from the same donors. Through analysis of the gene
expression profiles of the cultured OV/FT cells we identified a normal cell-of-origin gene signature that classified primary
ovarian cancers into OV-like and FT-like subgroups; this classification correlated with significant differences in clinical
outcomes. The identification of a prognostically significant gene expression signature derived solely from normal
untransformed cells is consistent with the hypothesis that the normal cell-of-origin may be a source of ovarian tumor
heterogeneity and the associated differences in tumor outcome.
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Introduction
There are marked differences in cellular morphology,
mutational spectrum and therapeutic response among the
various tumor subtypes that arise from the same organ. A
common explanation for these differences has been genetic
heterogeneity in the tumors of different patients [1]. Hence, the
identification and targeting of patient specific mutations
presents an attractive paradigm to guide the design of
personalized cancer therapeutics.
An emerging and complementary hypothesis is that phenotypic
differences among different subtypes of tumors arising in a single
tissue may also be imposed by cell autonomous features unique to
the normal cell-of-origin [2,3]. We and others have shown that
transformation of different normal cell subpopulations with
identical oncogenes can result in very different tumor behaviors.
For example, while some normal breast cell subpopulations gave
rise to highly tumorigenic and metastatic adenocarcinomas, other
breast cell subpopulations - isolated from the same patients and
transformed with identical oncogenes - gave rise to morpholog-
ically distinct, weakly tumorigenic and non-metastatic tumors,
suggesting that the normal cell-of-origin may be an important
factor in determining the associated tumor phenotype [2].
Human ovarian carcinomas are a particularly intriguing group
of neoplasms where the normal cell-of-origin may play an
important role. The different histopathologic subtypes of epithelial
ovarian cancer - serous, endometrioid, clear cell, mucinous,
transitional - have been thought to arise in a number of different
normal cell types including the ovarian surface epithelium and
epithelial lined ovarian inclusion cysts [4]. It also has been
suggested that some endometrioid and clear cell ovarian carcino-
mas may arise from ectopic uterine endometrium (endometriosis)
implanted on the ovary [5,6].
The fallopian tube fimbria epithelium has emerged as an
additional candidate cell-of-origin for high grade serous ovarian
carcinoma based on findings of morphologically dysplastic areas in
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[7], and the presence of p53 mutations that were identical between
these precursor lesions and the matched invasive ovarian
carcinomas in the same patients [8,9]. High grade serous
carcinomas are typically associated with p53 mutations [10,11],
and together these observations suggest that the fallopian tube
epithelium is a likely cell-of-origin for high grade serous ovarian
carcinoma [12].
While the above evidence suggests that ovarian carcinomas may
arise from a variety of different cell types, a gene expression
signature that could identify the putative cell-of-origin of a
particular type of ovarian cancer has been lacking. Thus, our
objective was to identify a gene expression signature that could
identify the normal cell-of-origin of ovarian carcinomas. Towards
this goal, it was necessary to develop a new cell culture medium
and methods to isolate and propagate normal ovarian epithelium
and fallopian tube epithelium as paired cultured cells from the same
individuals.
In the standard culture media that were available (e.g.,
MCDB 105/Medium 199, DMEM/Ham’s F12 and MEM) it
was not possible to culture normal ovarian surface epithelial
cells for more than 2–12 population doublings [13,14,15] and
normal fallopian tube epithelial cells were cultured for up to 10
population doublings [16] or three passages [17]. To our
knowledge previous investigators have not tested whether the
same media could be used to propagate both ovarian and
fallopian tube epithelial cells.
We previously described a novel chemically-defined cell
culture medium (WIT) that could support the long-term growth
of normal human breast epithelial cells without using undefined
components such as serum, feeder-layers, tissue extracts or
pharmacological reagents [2]. We tested the WIT medium
developed for breast cells and found that it did not support the
growth of normal ovarian or fallopian tube cells. In the current
study we describe the modification of the WIT medium (WIT-
fo) to culture normal ovarian epithelial and fallopian tube
epithelial cells. Using the newly developed WIT-fo media and
associated cell culture methods, we isolated and cultured paired
normal ovarian and fallopian tube epithelial cells from the same
individuals, identified a gene signature that distinguished these
cell types and used this information to classify primary ovarian
tumors as fallopian tube epithelial (FT)-like and ovarian
epithelial (OV)-like. The FT/OV-like classification provides
data to assess similarities between these normal cells and the
different ovarian cancer subtypes and importantly this classifi-
cation is associated with clinically relevant differences in patient
survival.
Materials and Methods
Ethics statement
Scrapings from the normal ovary and fallopian tube were
collected using a kittner from two donors who were treated at the
Brigham and Women’s Hospital for benign gynecologic disease
following an institutional review board approved protocol to
collect discarded tissues that waived the need for consent
(Supplementary Methods in File S1). The cells described in this
study are primary cell cultures established directly from tissue
samples collected during the course of the study.
The protocol for tumorigenesis experiments in immunocom-
promised mice was approved by the Harvard Standing Committee
on Animals (#04639). All experiments were performed in
compliance with relevant institutional and national guidelines
and regulations.
Culture of normal human fallopian tube and ovarian
epithelium
The most successful method for cell culture establishment was to
immediately place the fallopian tube and ovarian cells in WIT-fo
culture media and transfer the cells to a tissue culture flask with a
modified surface treatment (Primaria, BD, Bedford, MA) and
incubate at 37uC with 5% CO2 in ambient air. We strongly
recommend the use of Primaria culture plates since it was nearly
impossible to grow these cells using standard tissue culture plastic
ware.
WIT medium was previously described [2] (Stemgent, Cam-
bridge, MA) and WIT-fo is a modified version of this medium
optimized for fallopian tube and ovarian epithelial cells. To
prepare WIT-fo medium, the WIT medium was supplemented
with EGF (0.01 ug/mL, E9644, Sigma-Aldrich, St. Louis, MO),
Insulin (20 ug/mL, I0516, Sigma-Aldrich), Hydrocortisone
(0.5 ug/mL, H0888, Sigma-Aldrich), Cholera Toxin (25ng/mL,
227035, Calbiochem, EMD Millipore, Billerica, MA) and low
concentrations (0.5 – 1%) of heat inactivated fetal bovine serum
(HyClone, Thermo Fisher Scientific, Waltham, MA) (Supplemen-
tary Methods in File S1).
After 10–15 days, during which the medium was changed every
2–3 days, cells were lifted using 0.05% trypsin at room
temperature (,15 seconds exposure), then trypsin was inactivated
in 10% serum-containing medium, followed by centrifugation of
cells in polypropylene tubes (5006g, 4 minutes) to remove excess
trypsin and serum. Subcultures were established by seeding cells at
a minimum density of 1610
4/cm
2. Cell culture medium was
replaced 24 hrs after re-plating cells and every 48–72 hours
thereafter.
We tested several previously described media formulations to
culture ovarian and fallopian tube epithelial cells
[18,19,20,21,22,23], however, none of these media supported
the long-term propagation of normal ovarian or fallopian tube
epithelium (Supplementary Methods in File S1). Cell immortal-
ization and transformation of the normal cells with defined genetic
elements (following protocols approved by the Committee on
Microbiological Safety) was carried out as previously described [2]
(Supplementary Methods in File S1). The FNE, OCE, FNLER
and OCLER cells described in this manuscript will be available
from the Ince laboratory upon request. Experimental conditions
for western blotting, live cell imaging and FACS are described in
the Supplementary Methods in File S1.
Microarray analysis
Total RNA was extracted from cells that were cultured in
normal WIT-fo media conditions using the RNeasy Mini kit
(Qiagen, Valencia, CA) and hybridized onto Affymetrix HG U133
Plus 2.0 microarrays (Affymetrix Inc., Santa Clara, CA) (Supple-
mentary Methods in File S1). The FNE versus OCE signature was
compared to two publicly available ovarian cancer datasets that
were generated using similar methods in order to minimize
microarray platform and methodological bias; datasets generated
using total unamplified RNA, isolated from fresh frozen ovarian
cancers and profiled using Affymetrix microarray platforms were
selected. Microarrays of four hTERT immortalized cell lines
(OCE, FNE) from two patients (Gene Expression Omnibus (GEO)
GSE37648) as well as publicly available ovarian cancer gene
expression datasets by Wu et al. [24] (GSE6008) and Tothill et al.
[25] (GSE9891) were independently normalized using vsnrma
[26]. To identify genes that were differentially expressed between
paired hTERT immortalized FNE versus OCE, we applied a
modified t-test (False Discovery Rate [FDR] [27] adjusted
P,0.05) using the duplicate correlation function in Limma [28]
Normal Cell-of-Origin for Ovarian Cancer
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Methods in File S1).
To classify human ovarian tumors as FT-like and OV-like, we
selected the most highly significant ten probesets with unique gene
symbols that were over-expressed in either FNE or OCE. We then
calculated the sum of the normalized expression values of these ten
probesets in the ovarian cancer gene expression datasets by
weighting FNE genes by (+1) and OCE genes by (–1) resulting in
an overall signature expression score for each tumor (i.e., a tumor
with a higher score is more FT-like). We then fit a bimodal
distribution of Gaussian curves to this score using mixture
modeling [29] to classify ovarian tumors as FT-like or OV-like
(Supplementary Methods in File S1).
The clinical characteristics of patient tumors that were classified
as FT-like or OV-like were compared using ordinal logistic
regression (grade, stage) and Fisher’s Exact Test (histologic
subtype). To assess whether the FT-like/OV-like classification
was associated with differences in patient survival, univariate P-
values associated with Kaplan-Meier plots were calculated using
the log-rank test and multivariate P-values (adjusting for tumor
grade and stage, serous histologic subtype, patient age and the
presence of residual disease) were calculated using the Cox
proportional hazards test. Use the following link (http://compbio.
dfci.harvard.edu/pubs/OCFNLER/OCFNLER.zip) to download
the R script and associated datasets to replicate the microarray
analyses. Analyses were conducted using R (v2.10.1).
Analysis of tumorigenicity and metastasis
The analysis of tumorigenicity was carried out as previously
described [2]. Briefly, single-cell suspensions were prepared in a
Matrigel: WIT-fo mixture (1:1) and 1 million cells per 100 ml
volume were injected in one intraperitoneal (IP) and two
subcutaneous (SC) sites per mouse. Tumor cell injections were
performed on 6–8 week old female immunodeficient nude (Nu/
Nu) mice (Charles River Laboratories International, Inc, Wil-
mington, MA). Mice were euthanized by CO2 asphyxiation
followed by cervical dislocation. Tumors were harvested 5 to 9
weeks after implantation of tumorigenic cells from tissue culture
into IP and SC sites in nude mice.
Results
Establishment of normal primary ovarian and fallopian
tube epithelial cultures
We isolated paired normal ovarian and fallopian tube epithelial
cells collected from separate scrapings of the ovarian surface and
the fimbriated end of the fallopian tube using an endoscopic
kittner (Supplementary Methods in File S1) from two postmen-
opausal patients following an IRB approved protocol to collect
discarded tissues. Both patients were cancer-free and underwent
surgery for benign gynecologic conditions at the Brigham and
Women’s Hospital. In order to culture these cells, we modified
the chemically-defined WIT medium that we previously
described [2]; hereafter the culture medium optimized for
normal fallopian tube and ovarian epithelial cells is referred to
as WIT-fo. We compared the long-term growth of fallopian tube
and ovarian epithelial cells in WIT-fo medium with standard
media that have been previously used to culture ovarian
epithelium and fallopian tube epithelium [19,22] by plating
cells from the same donor in replicate plates using WIT-fo or
standard media (Fig. 1A and B).
It was possible to propagate normal ovarian epithelium and
fallopian tube epithelium in WIT-fo medium beyond 10 popula-
tion doublings, which corresponds to an .1000-fold net increase
in cell numbers. In contrast, ovarian and fallopian tube epithelium
could not be propagated in standard cell culture media beyond a
few population doublings. Hence, we were not able to establish
long-term cultures of normal ovarian epithelium or fallopian tube
epithelium in any of the previously described media, including the
unmodified WIT medium that was originally developed to culture
normal breast epithelial cells [2] (Supplementary Methods in File
S1).
Establishment and characterization of immortalized
ovarian and fallopian tube cultures
Immortalization of normal human ovarian epithelial cultures
has been previously attempted using viral oncogenes such as HPV
E6/E7 and SV40 T/t [30,31]; however, this method also increases
genomic instability and can cause the accumulation of DNA
mutations that could significantly alter the gene expression profiles
in the immortalized cells as compared with their finite lifespan
counterparts. Furthermore, these SV40 T/t and E6/E7 trans-
formed cells are not immortal because the genetic instability
eventually results in crisis and cell death within weeks to several
months of continuous culture [32].
As an alternative to viral oncogenes, we and others have shown
that ectopic hTERT expression can be used to immortalize
human cells without causing genomic instability [2,33]. We
introduced hTERT into the normal ovarian surface and fallopian
tube epithelial cells to create immortalized derivatives, hereafter
referred to as OCE (ovarian epithelium) and FNE (fallopian tube
non-ciliated epithelium). In order to characterize OCE and FNE
cells, we compared their phenotype with the staining patterns of
ovarian and fallopian tube cells in normal human tissues. Several
proteins including PAX8, FOXJ1 and CK7 are expressed in a cell
type specific manner in the normal human ovary and fallopian
tube [21,34,35]. CK7 is expressed in ovarian surface and inclusion
cyst epithelium as well as in all fallopian tube epithelium, and was
used to confirm the epithelial nature of the cultured cells. Many
ovarian inclusion cysts are entirely lined by PAX8
+ expressing
epithelial cells while ,5% of ovarian surface epithelial cells are
PAX8
+ [35]. In contrast, both cell types are FOXJ1 negative (Fig.
1C and D). In the fallopian tube the two major subpopulations of
epithelial cells (non-ciliated and ciliated) also can be distinguished
using these markers; nearly all non-ciliated cells are PAX8
+/
FOXJ1 ¯ while the ciliated cells are PAX8 ¯/FOXJ1
+ (Fig. 1E-G).
Immunoblotting and immunofluorescence staining of the OCE
and FNE cells showed that the staining profiles of the ovarian cells
were consistent with the ovarian surface/inclusion cyst epithelium
while the fallopian tube epithelial cells were similar to non-ciliated
epithelium (Fig. 2A and Fig. S1). Similarities between staining
profiles in the cultured OCE/FNE cells and ovarian and fallopian
tube cells in human tissues suggest that these staining patterns were
not an artifact of the culture conditions.
The morphology of the primary and hTERT immortalized
OCE and FNE cells in 2D culture appeared compact and
cobblestone-like and/or ‘pseudo-spindly’ depending on the
confluence of the culture and other factors such as the time since
the cells were split (Fig. S2A and S2B). We did not observe cilia in
the FNE cells. The immortalized OCE and FNE cells were
cultured continuously beyond 40 population doublings, which
corresponds to a 10
12-fold net increase in cell numbers (Fig. 2B
and 2C, blue lines). In contrast, replicate plates of the same cells
cultured in standard media (Supplemental Methods in File S1) or
when transferred to unmodified WIT medium ceased growing
after a few passages (Fig. 2B and 2C, red lines; Supplementary Fig.
S3 in File S1).
Normal Cell-of-Origin for Ovarian Cancer
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tube) gene signature to classify patient ovarian cancers
In order to investigate the cell-of-origin of human epithelial
ovarian carcinomas we compared the gene expression profiles
between FNE and OCE cells isolated from the same patients, and
found that 632 and 525 probesets were significantly up-regulated
in FNE or OCE cells, respectively (False Discovery Rate (FDR)
adjusted P,0.05, Tables S1 and S2). From these gene lists we
selected the ten most highly significant differentially expressed
probesets with unique gene symbols that discriminated between
FNE and OCE cells; five of the probesets were overexpressed in
FNE cells (gene symbols: DOK5, CD47, HS6ST3, DPP6, OSBPL3)
and five probesets were overexpressed in OCE cells (STC2, SFRP1,
SLC35F3, SHMT2, TMEM164).
In order to validate the FNE versus OCE normal cell-of-origin
signature we examined it in previously published gene expression
datasets that had profiled normal human fallopian tube epithelium
and normal ovarian surface epithelium [36,37,38,39]. It is worth
Figure 1. Culture and characterization of normal ovarian epithelial and fallopian tube epithelial cells. A, Replicate plates of normal
fallopian tube epithelial cells were cultured in WIT-fo medium (green and purple lines) or standard medium (red, grey lines, 1:1 mixture of Dulbecco’s
Modified Eagle’s Medium (DMEM) and Ham’s F12, supplemented with 0.1% BSA, 5% serum). In WIT-fo medium, normal fallopian tube epithelial cells
from two different patients divided continuously for at least 30 days and . 100 days and reached at least 12 and .20 population doublings
respectively (green and purple lines). In contrast, matched cells from the same donors growth arrested in the DMEM/Ham’s F12 medium (red, grey
lines). Normal fallopian tube epithelial cells were isolated from additional patients 3 and 4. B, Normal ovarian epithelial cells were cultured in WIT-fo
medium (purple and blue lines) or standard medium (red line, MCDB 105/Medium 199 (M199) (1:1 mixture) with 10% FBS and 2 mm l-glutamine).
Primary normal ovarian epithelial cells were from patients 2 and 3 (cells cultured in standard medium were from patient 3). Matched cells from
patient 3 growth arrested in the MCDB105/M199 medium (red line). C-D, Normal human ovarian tissue; immunoperoxidase staining of formalin-fixed
paraffin embedded (FFPE) sections with PAX8 demonstrates that ovarian inclusion cyst epithelium is PAX8
+ (brown nuclear stain) (C-D) while ovarian
surface epithelium is in general PAX8 negative (C), rare presence of rare Pax8 positive cells have been reposted on the ovarian surface. E, Normal
human fallopian tube tissue; double immunoperoxidase staining of FFPE sections shows ciliated cells are FOXJ1
+ (nuclear brown) and non-ciliated
cells are PAX8
+ (nuclear red). F, Normal human fallopian tube tissue; double immunoperoxidase staining of FFPE sections shows that ciliated cells are
FOXJ1
+ (nuclear brown) and non-ciliated cells are CK7
+ (cytoplasmic red) (scale bar (C-F) = 20 mM). G, Summary of cell type specific characterization
markers.
doi:10.1371/journal.pone.0080314.g001
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time - either ovarian or fallopian tube epithelial cells. Hence, the
ovarian and fallopian tube specific expression profiles were from
separate studies in which normal ovarian or fallopian tube
epithelial cells were isolated from different patients using various
collection methods. Despite these differences, the FNE/OCE
signature correctly classified all of the microdissected fallopian
tube epithelium samples as fallopian tube (FT)-like and all of the
cultured ovarian surface epithelial cells as ovary (OV)-like in two
different datasets (Fig. S4A and S4B in File S1). Four uncultured
normal ovarian surface epithelial brushings in the Wu et al. [24]
dataset also were correctly classified as OV-like (Fig. 3A). These
results indicated that the FNE/OCE normal cell-of-origin
signature could be applied across other data sets successfully.
We hypothesized that a residual cell-of-origin signature may be
retained in ovarian tumors which could be used to identify their
origin retrospectively. Hence, we used the FNE/OCE normal cell-
of-origin signature to classify 99 ovarian carcinomas in the Wu et
al. [24] dataset that included a representation of different
histologic subtypes and tumor grades. Due to array platform
differences 8/10 probesets were available for this analysis. In this
dataset the gene signature scores visualized in a density plot
showed a bimodal distribution which supports our binary
classification of ovarian tumors into normal FT-like and normal
OV-like subgroups (Fig. 3A). Comparisons between cultured cells
and tumor tissue gene expression profiles are difficult to carry out
for several reasons including the presence of stromal cells in the
tumor tissue which may influence the gene expression profile.
Fortunately, the tumors in the Wu dataset were microdissected
which permits a more direct comparison of gene expression
signatures between cultured OCE/FNE cells and ovarian tumor
cells.
Consistent with previous studies that suggested that high grade
serous cancers might arise in the fallopian tube, we observed that
the tumors that were classified as FT-like (similar to the normal
FNE cells) in the Wu dataset were of significantly higher stage,
higher grade and were predominantly composed of serous
adenocarcinomas (P#0.0004 for all comparisons) (Fig. 3B). In
contrast, OV-like tumors included predominantly non-serous
histologic subtypes and lower grade cancers. Thus, the normal
cell-of-origin gene expression signature appeared to split human
ovarian tumors in the Wu dataset into two distinct OV-like and
FT-like groups with different clinical and histopathological
characteristics.
The inclusion of additional probesets (e.g., 20 most highly
significant probesets in the FNE versus OCE comparison) to
calculate the signature score did not substantially alter the
results (data not shown) and is consistent with studies that have
shown that the inclusion of additional genes in a signature does
not always improve the robustness of the classification
[40,41,42]. Furthermore, using a different method to evaluate
the continuous cell-of-origin signature scores showed similar
results; the continuous scores differed significantly between
tumor histologic subtypes, grade and stage (P#0.005 for all
comparisons, Welch t-test) (Fig. S5A in File S1). We compared
these results with randomly permuted ten probeset signatures
(Fig. S5B in File S1) and none of the randomly permuted
signatures were associated with tumor histologic subtype, grade
or stage.
We examined the FNE/OCE cell-of-origin signature in a
second ovarian cancer gene expression dataset (Tothill et al.) [25].
In contrast to the Wu dataset, the tumors in the Tothill dataset
were not microdissected and only two histologic subtypes were
represented (246 serous tumors and 20 endometrioid tumors).
Possibly due to these differences, we observed a left skewed
distribution rather than a bimodal distribution in the signature
scores which is consistent with a small subgroup of OV-like tumors
(Fig. 3C). Nonetheless, in the Tothill dataset, the FT-like subgroup
contained mostly serous tumors (P=0.008) and there was a
suggestive enrichment for advanced stage tumors (P=0.07) (Fig.
3B, bottom panel). There was no association with tumor grade in
this dataset (P=0.87) possibly due to the small number of low
grade lesions (n=11). Examination of the continuous cell-of-origin
signature scores showed similar but non-significant results; there
was a suggestive shift to the right (indicating a higher score/more
FT-like) for serous versus endometrioid tumors and for stage III/
Figure 2. Immortalization of ovarian and fallopian tube epithelial cells with hTERT. A, Immunoblotting of whole cell extracts
demonstrates that hTERT immortalized ovarian epithelium (OCE) and fallopian tube non-ciliated epithelium (FNE) were CK7
+/PAX8
+/FOXJ1 ¯. Pig
kidney cells (LLC-PK1) were included as positive controls for FOXJ1. Each bar marks 52 kDa. B, OCE cells from patient 1 were cultured in WIT-fo
medium (blue line) or standard medium (red line, MCDB 105/Medium 199 (M199) (1:1 mixture) with 10% fetal bovine serum and 2 mm l-glutamine).
In WIT-fo medium OCE cells divided continuously for .150 days and reached 70 population doublings (blue line) while matched cells from the same
donor growth arrested in the control medium (red line). C, FNE cells from patient 1 were cultured in WIT-fo medium (blue line) or in standard medium
(red line, 1:1 mixture of Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F12, supplemented with 0.1% BSA and 5% serum). In WIT-fo medium
FNE cells divided continuously for .150 days and reached 40 population doublings (blue line). In contrast, matched cells from the same donor
growth arrested in the standard medium (red line). R
2 values indicate the fit of a polynomial line to the data points.
doi:10.1371/journal.pone.0080314.g002
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PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e80314Figure 3. Validation of FNE versus OCE cell-of-origin gene signature in two independent ovarian cancer datasets. A, Density plot
shows a bimodal distribution of signature scores for 99 ovarian tumor samples and four normal OSE scrapings from the Wu et al. dataset. Histograms
demonstrate the classification of these samples into normal ovarian epithelial like (OV-like) and normal fallopian tube epithelial like (FT-like)
subgroups (top pane), and show the range of signature scores by tumor histological subtype (lower panes). B, Association of the OV-like/FT-like
tumor classification in the Wu and Tothill datasets with clinical characteristics (P-values from logistic regression (grade, stage as ordinal variables) and
Fisher’s Exact test (histological subtype)). C, Density plot demonstrates a slight left skewing of the signature scores in the Tothill et al. dataset which
Normal Cell-of-Origin for Ovarian Cancer
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comparisons) and no association with tumor grade (data not
shown).
To evaluate whether originating from the ovary or fallopian
tube may be associated with differences in patient survival, we
compared the clinical outcomes between OV-like and FT-like
tumors in the Tothill dataset (survival data was not available in the
Wu dataset). We found that patients with FT-like tumors had
significantly worse disease-free survival (univariate log-rank
P=0.0003) and poorer overall survival (P=0.05) (Fig. 3D).
Importantly, after adjusting for tumor grade, stage, serous subtype,
patient age and residual disease in multivariate analysis, the OV/
FT-like subgroups were associated with significant differences in
disease-free survival (Cox proportional hazards P=0.01) but not
overall survival.
To further test the influence of the normal cell-of-origin on the
associated tumor phenotype, we created transformed deriva-
tives of the hTERT immortalized FNE and OCE cells by the
sequential introduction of SV40 Large T/small t (SV40T/t)
antigen and H-Ras as we described before [2,43]; these
tumorigenic cells are hereafter referred to as FNLER and
OCLER, respectively. Equal numbers of transformed FNLER
and OCLER cells were injected into the intraperitoneal space
and 26 subcutaneous sites of 24 total immunodeficient nude
(Nu/Nu) mice (15 and 9 mice were injected with OCLER or
FNLER, respectively, at two time points four months apart).
Experimental conditions were identical and rates of tumor
formation, tumor burden and metastases were similar at both
time points and therefore results were combined. Necropsy
analyses of mice 5–9 weeks after the tumor cell injection
revealed similar rates of xenograft formation, total tumor
burden (Table 1) and tumor histopathology (poorly differenti-
ated with focal micropapillary-like architecture) in both cell
types (Fig. 4). Both FNLER and OCLER derived tumors were
highly invasive into the surrounding intraperitoneal tissues (Fig.
S6A and S6B in File S1). Examination of the lungs from mice
bearing tumors (tumor mass $ 0.5g) revealed striking
differences in the propensity to develop lung metastases;
FNLER formed metastases in the lungs of 67% of mice
(n=6 mice evaluated) while isogenic OCLER formed metas-
tases in only 13% of the mice (n=8 mice evaluated) (P=0.04,
Mann-Whitney test). A higher number of mice were injected
with OCLER cells (versus FNLER) to increase the sample size
to investigate lung metastases inO C L E R .T h em e t a s t a t i ci n d e x
(number of metastatic cells/total tumor burden) for mouse
lungs also was higher in mice bearing FNLER tumors (Fig. S7
in File S1). The presence of the metastatic cells was confirmed
in the FFPE lungs with H&E and immunohistochemical
staining for p53 (Fig. S6C and S6D in File S1) and SV40
(data not shown). No difference was observed in the total
tumor burden or the time of tumor incubation between mice
injected with FNLER or OCLER that were examined for lung
metastases (Table S3 in File S1). These in vivo investigations
were exploratory as they were based on a small number of
mice; nevertheless, these data, combined with our previous
observations that FT-like patient tumors were associated with
worse outcome, are consistent with the hypothesis that the
normal cell of origin may play a role in determining the
associated tumor phenotype.
Discussion
The possibility that tumor behavior is influenced by the intrinsic
characteristics of the normal cell-of-origin in which the cancer-
promoting mutations emerge has been raised but has not been
extensively studied [2,44,45]. Although ovarian cancer has
traditionally been thought to arise in the ovarian surface or
inclusion cyst epithelium [4] or in endometriosis [5,6], the more
recent discovery of a candidate precursor lesion in the fallopian
tube fimbria epithelium suggests that a substantial number of
‘ovarian’ cancers may originate in the fallopian tube [8,12,46].
Indeed previous tissue-based studies have reported similarities in
gene expression between normal fallopian tube epithelium and
papillary serous carcinoma [47,48]. In the current study we
observed that .80% of serous carcinomas in two independent
ovarian cancer gene expression datasets were classified as fallopian
tube (FT)-like using the FNE versus OCE cell-of-origin signature.
This result provides independent support for the hypothesis that a
large proportion of high grade serous carcinomas may arise from
the non-ciliated fallopian tube epithelium [49].
Although based on small numbers we observed that $85% of
mucinous and clear cell tumors were classified as ovary (OV)-like,
suggesting that these tumors may arise from ovarian epithelium. In
contrast, endometrioid adenocarcinomas had a broader spectrum
of phenotypes. Based on the cell-of-origin signature in the Wu
dataset, 67% of endometrioid cancers were classified as OV-like.
In contrast, 65% of endometrioid cancers were in the FT-like
subgroup in the Tothill dataset. These observations suggest
multiple candidate cells-of-origin for endometrioid tumors.
In the xenograft model we observed that the transformed
FNLER and OCLER cells formed undifferentiated tumors with
focal micropapillary histology in mice. In previous studies fallopian
tube epithelium has been cultured using different standard media
conditions and using similar genetic alterations (including hTERT,
SV40T/t and HRAS +/– C-MYC); intriguingly, differences in the
resulting tumor histopathology have been reported - two of these
studies claimed that the histology of xenograft tumors was
consistent with human poorly differentiated serous tumors
[17,50] while the third study observed a poorly differentiated
mucinous histology [16]. Differences in the resulting tumor
phenotype may be due to different strains of mice or different
methodologies used to isolate and culture the fallopian tube
epithelial cells as we previously described in our breast cancer
model [2]. Regardless of the source, these observations suggest
that there are different cell subpopulations in the normal fallopian
tube that can give rise to tumors with different histologic
appearances and tumor behavior. Hence, these findings further
support the hypothesis that the normal cell-of-origin is an
important source of ovarian tumor heterogeneity.
The FNE versus OCE cell-of-origin signature included
probesets that were associated with 10 unique genes, five that
are over-expressed in FNE versus OCE (DOK5, CD47, HS6ST3,
DPP6, OSBPL3) and five that are over-expressed in OCE versus
FNE (STC2, SFRP1, SLC35F3, SHMT2, TMEM164). It remains to
be determined whether these genes are simply markers of the cell
type or they reflect functional differences between these cell types.
The ovary has been reported to have high levels of Stc2
(Stanniocalcin 2) mRNA expression [51] and in a rat model Luo
et al. [52] suggested that Stc2 may play a paracrine role in ovarian
suggests a small subpopulation (arrow) of OV-like tumors. Histograms demonstrate the distribution of signature scores in endometrioid and serous
tumors. D, Kaplan-Meier plots demonstrate significant differences in the disease-free survival and overall survival between OV-like and FT-like
subgroups in the Tothill dataset (univariate P-values from the log-rank test are displayed).
doi:10.1371/journal.pone.0080314.g003
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modulator of Wnt signaling and a stem cell marker, has been
reported in normal human ovarian surface epithelium [37] and in
fallopian tube fimbria epithelium [53]. CD47 is a cell surface
marker that is broadly expressed in normal adult tissues and in
human solid tumors including ovarian cancer [54].
In this study we developed a new medium (WIT-fo) and
associated methods to culture normal ovarian and fallopian tube
cells that were isolated from patients who were cancer-free. The
WIT-fo medium described in the current study is distinct from
other recently described media formulations which have been used
to culture ovarian or fallopian tube cells [16,17,55]. For example,
Liu et al. [55] described the culture of several cell types which
included one normal ovarian cell line but no tubal cells; however,
no data for population doublings of the ovarian line was provided.
This study used ROCK inhibitors to prevent cell death by
blocking apoptosis, hence the cell lines derived using this media
would be dependent on ROCK inhibitors and on mouse 3T3
fibroblasts as feeder layers. In contrast, we have no such drugs or
feeder layers in our cell culture model. Karst et al. [17] stated that
it was not possible to culture normal fallopian tube cells for .10
passages in their media. Furthermore, when they created
immortalized tubal cells by introducing a retroviral vector
encoding hTERT they noted that although hTERT alone
prevented senescence (#10 passages) it did not promote cell
growth to the extent that allowed for cell line expansion. Lastly,
the Shan et al. [16] study stated that it was not possible to culture
normal tubal cells for .10 population doublings in their
medium. These results differ from the culture conditions
developed in the current study in which hTERT immortalized
OCE and FNE cells were cultured continuously beyond 40
population doublings, which corresponds to a 10
12-fold net
increase in cell numbers.
Recent findings suggest that endometrioid and clear cell ovarian
carcinomas may arise from endometriosis implanted on the ovary
[5,6]. Endometriosis was not evaluated in this study because we
were not able to develop a cell culture medium for these cells.
Endometriosis lesions also are intrinsically different from normal
ovarian and fallopian tube epithelial cells because these lesions
have activated oncogenic pathways and mutations [12,56,57],
hence they are not entirely normal. Moreover, the precise normal
cell-of-origin for endometriosis is uncertain; it has been postulated
that endometriosis may arise due to trans-differentiation of
peritoneal mesothelial cells or from uterine endometrium that is
ectopically transplanted in the peritoneum [56]. For these reasons,
further studies will be needed to evaluate endometriosis as a
precursor lesion for ovarian cancer.
Observations in inherited cancer susceptibility syndromes
support an important relationship between the cell-of-origin and
tumor suppressor genes. For example, although many tumor
suppressor genes such as RB [58], BRCA1/2 [59] or WT1 [60] are
expressed ubiquitously in almost all tissues, their loss often gives
rise to tumors specifically in the retina, breast or ovary/fallopian
tube and kidney, respectively. These tissue-specific patterns of
tumorigenesis may reflect the susceptibility of the particular cell-of-
origin to a specific mutation. For example, it was shown that while
deletion of Rb caused apoptosis in most retinal cell types in mice, it
was tolerated in a specific subpopulation of retinal cells which were
the cell-of-origin for retinoblastoma [58]. Thus, these cell type
specific actions of Rb were the mechanism for the tissue specific
tumor development in inherited retinoblastoma.
The role of the cell-of-origin in sporadic cancers has been more
difficult to elucidate. One reason for this is that by definition the
process of carcinogenic transformation destroys the normal cell
from which the tumor initiates, which complicates retrospective
analyses of the cell-of-origin in tumor tissues. We used an
approach that isolates the candidate normal cells-of-origin and
Table 1. Tumor formation, tumor burden and ascites in the OCLER and FNLER xenograft model.
Cell line Genotype Tumor formation Tumor burden
a/mouse (g) ± s.d. Ascites present
b
Number of mice (%) Number of mice
OCLER hTERT, SV40 ER, HRAS
V12 13/15 (87) 3.24 6 2.08 0/13
FNLER hTERT, SV40 ER, HRAS
V12 6/9 (67) 4.94 6 2.36 3/6
P
c = 0.25 P
c= 0.33 P
c = 0.007
aValues shown are means 6 s.d. across all mice injected with each cell type that had any evaluable tumor mass (the sum of 16intraperitoneal and 26subcutaneous
sites per mouse).
bFormation of ascites was only evaluated among mice that developed tumors.
cP-values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pone.0080314.t001
Figure 4. OCLER and FNLER tumor histopathology in immu-
nodeficient nude (Nu/Nu) mice. A-B, Hematoxylin and eosin (H&E)
stains of representative formalin-fixed paraffin-embedded (FFPE) tumor
sections from OCLER (A) and FNLER (B) xenografts revealed focal
micropapillary structures. The predominant morphology was diffuse
sheets of cells with a poorly differentiated tumor architecture (scale bar
=2 0mM). C-D, PAX8 immunoperoxidase stains of representative FFPE
tumor sections from OCLER (C) and FNLER (D) xenografts confirmed
that xenografts retained their PAX8 expression (scale bar = 20 mM).
doi:10.1371/journal.pone.0080314.g004
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While simple as a concept, studies of normal ovarian and fallopian
tube epithelial cells have been hampered in part by the lack of a
robust cell culture system. To our knowledge the continuous long-
term culture of normal fallopian tube epithelium has not been
possible using the previously described cell culture media.
In summary, we have described a new culture media and
methods that permitted the development of an experimental
model of paired hTERT immortalized human ovarian (OCE) and
fallopian tube (FNE) epithelial cells from donors who were cancer-
free. We observed that patients with FT-like tumors had
significantly worse disease-free survival even after adjusting for
important prognostic factors such as tumor stage and grade.
Notably, the FNE versus OCE signature was derived from normal
hTERT immortalized cells that are untransformed and non-
tumorigenic. These findings suggest that an intrinsic network of
genes expressed by the normal cell-of-origin and retained by the
tumor may play an important role in determining the malignant
tumor phenotype. These findings suggest that studies of tumor
mutations coupled with the knowledge about the cell-of-origin
context may be needed to gain a full appreciation of factors
leading to differences in tumor behavior.
Supporting Information
Figure S1 Immunofluorescence staining of cultured
OCE and FNE cells for PAX8 and FOXJ1. A-B, Immuno-
fluorescence staining shows that OCE and FNE cells are PAX8
+/
FOXJ1 ¯ while IHOSE cells (immortalized using HPV E6/E7
[Tsao et al. 1995, Exp Cell Res 218: 499-507]) were PAX8 ¯. FNE1
and FNE2 indicate that these cells were derived from patients 1
and 2, respectively. The positive control for FOXJ1 (ciliated pig
kidney cells [i.e., LLC-PK1]) all showed positive nuclear staining
(data not shown). Experimental conditions for immunofluores-
cence are detailed in the ‘Antibodies and experimental conditions’
table in the Supplementary Methods in File S1.
(TIF)
Figure S2 Morphology of primary and hTERT-immor-
talized FNE and OCE cells in WIT-fo medium. A,
Photographs at 106 magnification. B, Cropped and enlarged
photographs (white frames in Fig. S2A).
(TIF)
Table S1 Probesets that were up-regulated (n=632) in
comparisons of immortalized fallopian tube non-ciliated
epithelium (FNE) versus immortalized ovarian epitheli-
um (OCE) (FDR adjusted P,0.05).
(PDF)
Table S2 Probesets that were up-regulated (n=525) in
immortalized ovarian epithelium (OCE) as compared
with immortalized fallopian tube non-ciliated epitheli-
um (FNE) cells (FDR adjusted P,0.05).
(PDF)
File S1 Combined Supporting Information file includ-
ing the Supplementary Methods and the specified
Supplementary Tables and Figures.
(DOCX)
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